Tier 2 — strong

The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update

Qin Song, Xiaofeng Zhou, Kexin Xu, Sishi Liu, Xinqiang Zhu, Jun Yang
Advances in Nutrition 2023 14(6):1416–1435

Bibliography

PubMed
PMID 37619764
PubMed Central
PMC10721522
DOI
10.1016/j.advnut.2023.08.008
Funding
Supported in part by the National Natural Science Foundation of China (31971138, 32270186, 62202136), Zhejiang Provincial Natural Science Foundation (LZ19H260001, LQY20F030001), and Health Commission of Zhejiang Province (2022506699).
Competing interests
The authors reported no conflicts of interest.

Study snapshot

DesignNarrative review of NMN/NAD+ biology, preclinical evidence, published human clinical trials and clinical-trial registries.
ModelPublished human NMN clinical trials plus completed-unpublished and ongoing trial registrations available at the review's search period.
Sample10 published human clinical trials were summarized; the authors also identified 13 completed but unpublished and 11 ongoing trials.
InterventionMultiple oral NMN doses, populations and durations across the human clinical-trial literature available through 2023.
DurationVaried across the reviewed human trials.
EndpointsHuman NMN safety; Blood NAD+ and metabolites; Insulin sensitivity; Physical function; Sleep; Cardiovascular and metabolic outcomes; Research gaps

What the study showed, in plain terms

This 2023 review is a useful historical map of the early human NMN literature. It summarized 10 published human trials and separately identified 13 completed but unpublished and 11 ongoing registered studies.

The authors concluded that short-term oral NMN had generally been well tolerated in the available trials, while evidence for broad anti-aging effects in humans remained limited.

Its registry mapping is useful for identifying publication gaps, but registered or completed-unpublished trials are not treated as efficacy evidence in the Biohack Blueprint corpus.

Key findings

  • Ten published human NMN clinical trials were summarized.
  • Thirteen completed but unpublished and 11 ongoing registered trials were identified separately.
  • Available short-term human trials generally suggested tolerability across the studied doses and populations.
  • Human evidence for broad anti-aging claims remained sparse and substantially weaker than the preclinical literature.
  • The authors called for larger, longer and better-designed trials in more diverse populations.

What this study can and cannot tell us

This is a narrative review rather than a systematic review or meta-analysis, and its evidence map is now historically dated by newer trials published after 2023.

Registry records demonstrate research activity, not efficacy; unpublished and ongoing trials should not be counted as positive evidence.

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology